CUE: Cue Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Cue Biopharma reported Q3 2026 results: revenue $0.1M, net loss $50.0M, R&D expenses $17.0M, and cash $57.9M. The company expects a $3.0M payment in Q4 2026. CUE-401 began clinical trials, and FDA cleared CUE-221 IND application.

Original reporting
Published Nov 16, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CUE
Bearish
high confidence
Mentioned
$CUE
Relevance
8/10
AlphAI data visualization · based on quantisnow.com
Decision brief

The 30-second read

$CUEBearishMed
01

Why it matters

The filing updates the company’s near-term financial runway (cash $57.9M) and highlights a larger quarterly net loss alongside early clinical momentum (CUE-401 first-in-human dosing) and an FDA IND clearance (CUE-221 for food allergy).

02

Market read

Traders get a fresh quarterly P&L and cash update plus near-term catalyst timing (ImmunoScape payment in Q4) that can influence valuation and financing-risk expectations.

03

What to watch

Non-cash stock compensation inflated the loss; traders may focus more on cash burn trajectory and the probability/timing of future milestone payments rather than GAAP net loss alone.

Relevance 8/10Novelty 7/10Timing: after-hours filing on 2026-11-16, for positioning into the next trading session

Background

The article summarizes Cue Biopharma’s SEC Form 8-K for Q3 2026 results, including financial statements and key clinical/regulatory updates.

Company-level read

Ticker impact

$CUEBearishHigh confidence
Context

Cue Biopharma reported Q3 revenue of $0.1M (down from $2.1M) and net loss of $50.0M, citing higher R&D and stock comp.

Expected impact

Likely near-term pressure as investors weigh the larger loss and revenue decline against early clinical progress and expected ImmunoScape cash.

Evidence & confidence

The filing provides specific quarterly P&L and cash figures plus concrete clinical/regulatory milestones, making the risk-reward update actionable for traders.

Market effects

Biotech investors may recalibrate risk appetite for pre-revenue or early-stage programs when quarterly cash burn and collaboration revenue weaken.

No clear regional spillover beyond US small-cap biotech sentiment.

Limited, as the disclosure is company-specific and not tied to a global macro or cross-border regulatory event.

Counterpoint

The revenue drop may be timing-related under the Boehringer Ingelheim collaboration, while the company’s cash balance and upcoming ImmunoScape installment reduce immediate financing risk.

Key entities

  • Cue Biopharma Inc.

    Subject of the SEC Form 8-K, reporting Q3 2026 financial results and clinical/regulatory milestones.

  • CUE-401

    Began first-in-human dosing, reaching a key 2026 milestone per the filing summary.

  • CUE-221

    FDA cleared the IND application for food allergy per the filing summary.

  • ImmunoScape payment

    Expected $3.0M in Q4 2026 as part of a total $5.5M payable in installments.

  • Boehringer Ingelheim

    Collaboration referenced as the source of licensing revenue that declined in Q3.

Related articles

$CUEMed

Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights • CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and fo

$CUEMedAI 8/10

Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?

Cue Biopharma (CUE) reported positive Phase 2 results for CUE-221 in treating chronic hives, with 54% of patients achieving complete hive resolution vs. 11% on placebo. The drug showed sustained relief 12 weeks post-treatment, with 60% of patients in the highest-dose group remaining hive-free. No serious adverse events were reported. The company plans a Phase 2b/3 study and has $67.4M in cash after recent financing.

$CUEMedAI 9/10

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling stu